Prandin Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for Novo Nordisk's diabetes therapy Prandin (repaglinide) was filed Feb. 10, according to FDA's April 19 updated list of filings
You may also be interested in...
Sandoz will convert its ANDA for modafinil to a Paragraph III certification and will not market its generic until Provigil patent expiry in 2014, Cephalon says. However, other generic competition is expected in mid-2006. Sun also drops challenge of Gabitril (tiagabine).
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.